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Background: Secondary prevention after stroke and transient ischemic attack (TIA) is essential in order to reduce
morbidity and mortality. Secondary stroke prevention studies have, however, been fairly small, or performed as
clinical trials with non-representative patient selection. Long-term follow-up data is also limited. A nurse-led
follow-up for risk factor improvement may be effective but the evidence is limited. The aims of this study are to
perform an adequately sized, nurse-led, long-term secondary preventive follow-up with a population-based
inclusion of stroke and TIA patients. The focus will be on blood pressure and lipid control as well as tobacco use
and physical activity.
Methods: A randomized, controlled, long-term, population-based trial with two parallel groups. The patients will be
included during the initial hospital stay. Important outcome variables are sitting systolic and diastolic blood
pressure, LDL cholesterol and total cholesterol. Outcomes will be measured after 12, 24 and 36 months of follow-up.
Trained nurses will manage the intervention group with a focus on reaching set treatment goals as soon as possible.
The control group will receive usual care. At least 200 patients will be included in each group, in order to reliably
detect a difference in mean systolic blood pressure of 5 mmHg. This sample size is also adequate for detection of
clinically meaningful group differences in the other outcomes.
Discussion: This study will test the hypothesis that a nurse-led, long-term follow-up after stroke with a focus on
reaching set treatment goals as soon as possible, is an effective secondary preventive method. If proven effective,
this method could be implemented in general practice at a low cost.
Trial registration: Current Controlled Trials ISRCTN23868518
Keywords: Stroke, Secondary prevention, Cardiovascular diseases, Randomized controlled trialBackground
The risk of stroke recurrence, myocardial infarction and
death after stroke is high [1,2]. Secondary prevention after
stroke is essential in order to reduce morbidity and morta-
lity, consequently leading to reduced costs to society.
There are a number of evidence based treatment strategies
for secondary prevention after stroke [3]. Risk factor* Correspondence: thomas.mooe@medicin.umu.se
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reproduction in any medium, provided the ormodification may reduce the risk of stroke recurrence by
up to 80% [4]. Despite these facts, secondary stroke pre-
vention studies have mostly been performed as clinical
trials with non-representative patient selection, for example
concerning age and co-morbidity [5]. There is considerable
literature about non-pharmacological interventions but a
paucity of data concerning the implementation of proven
pharmacological interventions in patients representative of
clinical praxis [6]. The number of long-term follow-up
studies of secondary prevention after stroke is, to date,
limited.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stroke is difficult. There are limitations in terms of
compliance and the proportion of patients achieving set
treatment goals in usual care [5,7]. Even though adher-
ence to prescribed medication may be quite high in
some cohorts of stroke patients [8], the proportion
achieving set treatment goals among the various risk
factors has been less studied. A strategy to improve sec-
ondary prevention results by early interventions shows
potential [9]. On the other hand, there is evidence that
even high quality secondary preventive measures
initiated while patients are hospitalized are no guaran-
tee of a successful outcome after discharge [10]. Further
research in this area is essential.
There is limited evidence that nurse-led follow up for
risk factor improvement after stroke has a positive
outcome [11]. In order to improve secondary prevention
after stroke, we have designed a trial with the following
components:
1. Population-based. All patients in the county of
Jämtland, Sweden, admitted to the county hospital
with transient ischemic attack (TIA) or stroke will be
considered for inclusion in the study, regardless of
age, gender or co-morbidity.
2. The study will be randomized with a nurse-led
intervention group and a control group being seen by
their general practitioner for usual medical care.
3. The intervention is based on telephone follow-ups by
a stroke nurse, in order to facilitate implementation
and minimize the necessary resources.
4. A routine of promptly adjusting medication in order
to achieve set treatment goals for secondary stroke
prevention will be established.
5. Duration of the study. A follow-up with risk factor
evaluation after 12, 24 and 36 months is planned.
In this nurse-based telephone follow-up study, we
hypothesized that the outcome, in terms of risk factor
control, would be better in the intervention group.
Ethics approval has been received from the Ethics
Committee, Umea University.
This paper presents the design of the study according
to the CONSORT requirements [12].Methods/design
Trial design
A randomized, controlled trial with two parallel groups
and an allocation ratio of 1:1.Participants
All patients living in the county of Jämtland, Sweden,
who were hospitalized with a diagnosis of stroke(ischemic or hemorrhagic) or TIA will be assessed for
inclusion. Östersund hospital is the only hospital in the
county and all patients, those in terminal care excluded,
with symptoms of a suspected TIA or stroke, are
referred here for diagnostic evaluation. It is a rural
catchment area with a population of approximately
125,000 inhabitants. A routine for identification of all
patients in the hospital with a possible TIA or stroke,
based on performed brain computed tomography exami-
nations, has been established. During a three-month test
period the study nurses identified all patients with a final
TIA or stroke diagnosis. All patients physically and
mentally capable of communicating by telephone will be
eligible. This means that patients suffering from aphasia,
dementia and deafness will be excluded. The other
exclusion criteria are severe, often terminal, disease, and
participation in another on-going trial.
Interventions
All eligible patients will be informed about the study
and asked to give a written informed consent. They will
receive standard information about stroke concerning
the pathophysiology and risk factors according to estab-
lished clinical praxis during their hospitalization. They
will also be offered a follow-up visit to a stroke nurse
and an outpatient follow-up according to normal care
procedures.
Patients randomized to the intervention group will be
contacted by a study nurse by phone one month after
discharge. Before the call, a blood sample for lipids will
be taken and a standardized blood pressure control will
be performed. Blood pressure will be measured after five
minutes in the sitting position and after one minute
standing. The tests will be performed by a district nurse,
or, for patients in the intervention group living close to
the hospital, by a study nurse. Self-reported compliance
with medication will be recorded. During the call the
patient will be informed about the test results and
whether a change in medication is necessary. Tobacco
use, physical activity and dietary habits will be discussed.
Smoking cessation will be encouraged and supported.
Physical activity of moderate intensity for 30 minutes or
more, most days of the week will be encouraged, but
also adjusted to the individual patient’s capacity. Dietary
advice to reduce saturated fat and increase the intake of
fruit and vegetables will be given. If the patient’s choles-
terol or blood pressure values are higher than antici-
pated, medication will be adjusted after contact from a
study physician. Repeated tests will be taken within
approximately four weeks and further adjustments made
if necessary until target values are reached or no further
changes can be considered realistic. The same routine,
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(optionally <130/<80 mmHg in patients at very high risk,
that is, diabetic subjects), total cholesterol <4.5 mmol/l,
LDL <2.5 mmol/l [13,14].
Patients randomized to the usual care group will also
be contacted by phone one month following discharge
after blood pressure and lipid profile have been checked.
Self-reported compliance, tobacco use and physical activity
will be recorded. All medical care will be given by their
treating physician, usually a general practitioner, who will
receive the test results (lipid profile and blood pressure),
and no additional intervention will be given as a result
of participation in the study. The same routine, with an
Hb1C test added, will be applied after 12, 24 and 36
months, Figure 1.1 month fo-up 
Interview. BP. 
Lipids. Titration to 
target by nurse
12 month fo-up 
Interview. BP. 
Lipids. Titration to 
target by nurse
24 month fo-up 
Interview. BP. 
Lipids. Titration to 
target by nurse
36 month fo-up 
Interview. BP. 
Lipids. Titration to 












36 month fo-up 
Interview. BP. Outcomes
Outcomes will be measured after 12, 24 and 36 months
of follow-up. Outcome variables are sitting systolic and
diastolic blood pressure, LDL cholesterol and total chol-
esterol, as well as the proportion of patients achieving
the set target for these variables. Standing systolic and
diastolic blood pressure, smoking rates, the proportion
of patients treated with different secondary preventive
drugs, diabetes control by Hb1C, change in body mass
index (BMI) and physical activity will also be measured.
Sitting systolic blood pressure at 36 months will be
analyzed as the primary outcome. The analyses of the
secondary outcomes will be exploratory.
Blood pressures measurements are standardized as
described above. LDL values are calculated from the
serum concentrations of cholesterol and fasting trigly-
cerides using the Friedewald formula. Smoking (yes/no)
and physical activity (duration/week) are self-reported.
Deaths are available in the hospital records and will be
recorded in order to detect any survival difference be-
tween groups.target by nurse
Lipids. 
Usual Care
Figure 1 Study flow chart. BP = blood pressure measurement.
Sample size
To reliably detect a difference between groups in
mean systolic blood pressure of 5 mmHg requires
study groups of 180 participants (standard deviation
19, mean systolic blood pressure 140 versus 135,
alpha 0.05 two-tailed, power 80%). Study groups of at
least 200 participants are planned to allow for drop-outs.
This sample size is also adequate for detection of
clinically meaningful group differences in lipid values
(0.3 mmol/l, standard deviation 1.0), smoking rates
(10%), proportion reaching treatment goals (10%),
change in BMI (1.0, standard deviation 4.0) and
change in physical activity (10%, proportion in a given
activity level), calculated with two-tailed alpha 0.05,
power 80%.Randomization
The random allocation sequence will be computer
generated in blocks of four and stratified for gender and
degree of disability (modified Rankin scale <3 and ≥3). A
sealed, colored envelope will have a serial number on
the outside and a folded sheet of paper inside with the
group allocation written on it: this will be impossible to
read from the outside. The study coordinators will enroll
participants and assign them to interventions in order
according to the serial number. The random allocation
sequence will be computer generated by the study
manager who is not involved in the randomization
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be controlled for ten patients.
Statistical methods
The primary analysis will be performed according to the
intention-to-treat principle using a linear regression
model adjusting for gender and degree of disability. The
adjustment is made in order to reflect the stratified
randomization process. Per protocol analyses will also be
performed. Secondary outcomes will be analyzed using
the primary analysis model when continuous, and using
a logistic regression model, adjusting for the same
covariates, when outcomes are binary. In order to assess
whether there are indications of differential treatment
effects across subgroups (age, gender, co-morbidity, level
of education and social classification), tests for inter-
action will be performed, although this aim is secondary
because the study is not powered for this particular
purpose. Adjustment for relevant baseline covariates will
be performed in additional exploratory analyses of
primary and secondary outcomes in order to evaluate
the effect of possible baseline imbalance. All tests will be
two-sided and a P-value of <0.05 will be considered
significant.
Discussion
Stroke is one of the major diseases in the current ageing
population, with substantial consequences for individuals
and society. The knowledge of secondary preventive
measures to prevent further disease in stroke patients is
strikingly low. Further research in the areas of compli-
ance, the possibility of participation in secondary
preventive studies and the possibility of reaching treat-
ment goals in a cohort of stroke patients representative
for clinical praxis is absolutely necessary.
This study covers all patients in one Swedish county,
who after TIA or stroke, will be eligible for inclusion,
thus avoiding selection bias. This allows us to study even
very old and very sick stroke patients, who are usually
not included in randomized stroke studies. Their ability
to participate in secondary prevention programs and
their tolerability of medication when attempting to
achieve set treatment goals are of great interest as these
have significant consequences for health economics and
mortality and morbidity rates.
The study design has several other advantages. Rando-
mization of the patients soon after the stroke or TIA
allows us to study the acute phase as well as to perform
a long-term follow-up. By establishing an early contact,
no patient is expected to be lost to follow-up. The
immediate recruitment and the logistics to include
each and every stroke and TIA patient will show the
true proportion of possible participants in the secondary
preventive program.As it is well known that information and team rehabili-
tation after stroke affects the outcome, the study is
designed so that each eligible patient will receive the same
present standard of care regardless of randomization
group.
Our intention is to combine a nurse-led life-style
intervention with a rapid pharmaceutical titration model
aiming to achieve set treatment goals of the most im-
portant risk factors after stroke. The long-term follow-up
and the relatively large number of patients involved
will provide important new data in the field of improving
secondary prevention after stroke. Cost-effectiveness of
this method of handling stroke follow-up can be studied,
and we are of the opinion that this method - if proven
effective - could be implemented in general clinical
practice at a low cost. The study logistics are deliberately
made as simple as possible in order to be generalizable to
the Swedish as well as to other national health care
systems. Although the study is performed in a single
county, the information on better control of standard





TIA: Transient ischemic attack; BMI: Body mass index; LDL: Low-density
lipoprotein.
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